Tacrolimus—Clarithromycin Interaction in a Patient Receiving Bone Marrow Transplantation

Abstract

Get full access to this article

View all access options for this article.

References

Lee

Kennedy

. Tacrolimus: An alternative for graft-versus-host disease prevention. Ann Pharmacother 2000;34: 377–81.

Mignat

. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997;16: 267–78.

Masuda

Uemoto

Hashida

Inomata

Tanaka

Inui

. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000;68: 98–103.

Jacobson

Ratanatharathorn

Uberti

Brundage

. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 2001;28: 753–8.

Przepiorka

Nash

Wingard

Zhu

Maher

Fitzsimmons

Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Bone Marrow Transplant 1999;5: 94–7.

Wolter

Wagner

Philipp

Fritschka

. Interaction between FK506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994;47: 207–8.

Gomez

Alvarez

Errasti

Lavilla

Garcia

Ballester

Acute tacrolimus nephrotoxicity in renal transplant patients treatment with clarithromycin. Transplant Proc 1999;31: 2250–1.

Katari

Magnone

Shapiro

Jordan

Scantlebury

Vivas

Clinical features of acute reversible tacrolimus nephrotoxicity in kidney transplantation recipients. Clin Transplant 1997;11: 237–42.

Naranjo

Busto

Sellers

Sandor

Ruiz

Roberts

A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: 239–45.